SRRK - Scholar Rock Is At Phase 2 $1 Billion Is Too Expensive

• Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important.
• SRRK tested a total of 58 employees in Phase 2. I would expect the company to test many more patients in Phase 3.
• In 2019, SPINRAZA annual sales may equal more than $2 billion. ZOLGENSMA sales were equal to $361 million in 2019.
• SRRK’s product may obtain annual revenue between $400 million and $1 billion.
• Recently, SRRK's total enterprise value increased to more than $1 billion. It is, in my view, too large. The market appears to be discounting that the drug will be approved by the FDA.

For further details see: